Study to Investigate the Safety and Efficacy of BRII-835 and BRII-179 Combination Therapy Treating Chronic Hepatitis B Virus (HBV) Infection
Sponsored by Brii Biosciences Limited
About this trial
Last updated 2 years ago
Study ID
BRII-179-835-001
Status
Completed
Type
Interventional
Phase
Phase 2
Placebo
No
Accepting
18 to 60 Years
All Sexes
Trial Timing
Ended 3 years ago
What is this trial about?
This is an open label, randomized, parallel-group study to evaluate the safety and efficacy of combination treatment BRII-835 (VIR-2218) and BRII-179 (VBI-2601) in adult participants with chronic HBV infection
What are the participation requirements?
Inclusion Criteria
* Male or female aged 18 - 60
* Body mass index ≥ 18 kg/m^2 and ≤ 32 kg/m^2
* Chronic HBV infection as defined by a positive serum HBsAg for ≥ 6 months
Exclusion Criteria
* Any clinically significant chronic or acute medical condition that makes the volunteer unsuitable for participation
* Significant fibrosis or cirrhosis
* History or evidence of drug or alcohol abuse
* History of intolerance to SC or IM injection
* History of chronic liver disease from any cause other than chronic HBV infection
* History of hepatic decompensation